Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 5906 record(s)

Req # A-2024-000028

Adverse Drug Reactions (ADRs) for Rosuvastatin-40. Report numbers: 000657015, 000702528. ADRs for Rosuvastatin-10. Report numbers: 000675846, 000928844. ADRs for Rosuvastatin-5. Report numbers: 000698101, 000705573. ADRs for Rosuvastatin-20. Report numbers: 000709470, 000720165.

Organization: Health Canada

29 page(s)
April 2024

Req # A-2024-000032

Adverse Drug Reactions (ADRs) for IBUPROFEN. Report numbers: 001049833, 001051635, 001052031, 001052040, 001052619, 001050859, 001053224, 001055320, 001065019, 001065607.

Organization: Health Canada

76 page(s)
April 2024

Req # A-2024-000068

Adverse Drug Reaction (ADR) for YESCARTA. Report number: 001076510.

Organization: Health Canada

3 page(s)
April 2024

Req # A-2024-013

Pursuant to the Access to Information Act, R.S.C. 1985, c. A-1, I hereby request access to the following records: 1. A copy of the agreement(s) involving the Canada Infrastructure Bank (CIB), Macquarie Asset Management, Porter Aviation Holdings Inc., the Montreal Metropolitan Airport (YHU), and/or any related companies in relation to the investment project for the development of a new domestic airport terminal at the Montreal Metropolitan Airport (YHU). 2. A copy of any reports, plans, prospectuses, or similar documents related to the above-referenced investment project.

Organization: Canada Infrastructure Bank

0 page(s)
March 2024

Req # A-2023-00040

Provide from January 1, 2023, to present, any available projected costs for running the next election. Additionally, please provide any documents pertaining to any significant changes in election procedures for dealing with election interference or reaching out to people with no fixed address (exclude drafts, except for the latest one).

Organization: Elections Canada

0 page(s)
March 2024

Req # A-2023-00068

Policy interpretations related to large virtual currency transaction reporting

Organization: Financial Transactions and Reports Analysis Centre of Canada

105 page(s)
March 2024

Req # A-2023-00072

Various 2022 and 2023 statistics on money services businesses; relating to the amount of businesses registered, number of employees, policy interpretations requested, volume of transactions, and deficiencies found in compliance examinations

Organization: Financial Transactions and Reports Analysis Centre of Canada

5 page(s)
March 2024

Req # A-2023-00089

Questions, answers and interpretations concerning politically exposed persons

Organization: Financial Transactions and Reports Analysis Centre of Canada

78 page(s)
March 2024

Req # A-2016-000420

Documents relating to Health Canada’s approval of INFLECTRA (Drug Identification Number (DIN) # 02419475): All Health Canada reviewers reports and reviewer comments; and all minutes from any pre-Supplement to a New Drug Submission (SNDS) meetings between Celltrion (health care company) and Health Canada between September 1, 2014 and June 30, 2015.

Organization: Health Canada

299 page(s)
March 2024

Req # A-2019-001464

All domestic Adverse Drug Reaction (ADR) reports for Tetanus, Diphtheria and Pertussis (Tdap) Hepatitis B, Measles, Mumps and Rubella (MMR), Varicelli, Inactivated Polio Vaccine (IPV), Diphtheria, Tetanus and Pertussis (DTaP), Flu for the period of October 1, 2018 - end of March 2019.

Organization: Health Canada

3917 page(s)
March 2024
Date modified: